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In the lower graph (Fig. 1C), we can observe an increase in ΔADC as 
dose increases, although the data are not relevant enough because of 
the few number of patients analyzed. 
Conclusions: ADC maps can be used not only for treatment 
assessment, but also for quantification of tumour response voxel by 
voxel. Even more, the joint use of MRI diffusion data and PET/CT can 
be useful for delimiting the hypoxic areas, due to glucose 
consumption enhancement by Pasteur effect. The main weakness of 
this method is the rigid registration process, and non rigid registration 
algorithms are needed for the registration of highly distorted images 
from diffusion studies. 
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Purpose/Objective: In radiotherapy (RT) of prostate cancer the key 
organs at risk (ORs) – the rectum and the bladder – display 
considerable motion, which may influence the dose/volume 
parameters predicting for morbidity. In this study we compare motion-
inclusive doses to planned doses for the rectum and bladder and 
explore their associations with prospectively recorded morbidity.  
Materials and Methods: The study included 38 prostate cancer 
patients treated with hypo-fractionated image-guided intensity-
modulated RT that had an average of nine repeat CT scans acquired 
during treatment. These scans were registered to the respective 
treatment planning CT (pCT) followed by a new dose calculation from 
which motion-inclusive dose distributions were derived. The pCT 
volumes, the treatment course averaged volumes as well as the 
planned and motion-inclusive doses were associated with acute and 
late morbidity (morbidity cut-off: ≥ Grade 2). 
Results: Acute rectal morbidity (observed in 29% of cases) was 
significantly associated with both smaller treatment course averaged 
rectal volumes (population median: 75 vs. 94 cm-3) and the motion-
inclusive volume receiving doses close to the prescription dose (2Gy-
equivalent dose of 76 Gy).  
Conclusions: Variation in rectum and bladder volumes leads to 
deviations between planned and delivered dose/volume parameters 
that should be accounted for to improve the ability to predict 
morbidity following RT.  
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Purpose/Objective: Biomarkers extracted from functional images may 
be subject to cross-institutional variations, and are thus in need of 
standardization. Pharmacokinetic parameters derived from dynamic 
contrast enhanced (DCE) MRI of cervical cancers have shown a 
predictive value in identifying patients at risk of relapse following 
radiotherapy. The aim of the current work was to compare 
pharmacokinetic parameters obtained from DCEMR images, acquired 
at different institutions, of patients with locally advanced cervical 
cancers. 
Materials and Methods: DCEMRI images from 2 centers have so far 
been collected. At center 1 (Oslo University Hospital), 78 patients 
have been included. Here, DCEMRI was performed using Magnevist 
(Gadopentetate Dimeglumine) as contrast agent and an FSPGR 
sequence with temporal resolution of 15 s and spatial resolution of 
0.8x0.8x5 mm at a 1.5T Signa Horizon LX scanner (GE Medical 
Systems). At center 2 (University Medical Center, Utrecht), 23 
patients have been included. In this case, DCEMRI was performed 
using Magnevist and a 3D FLASH sequence with 2.4 s temporal 
resolution and spatial resolution 0.9x0.9x3mm at a 1.5T Gyroscan NT 
Intera scanner (Philips Medical Systems). Pharmacokinetic analysis 
with the ‘Brix’ model was performed in an identical manner for the 
two cohorts. The model analysis of the dynamic series was done voxel 
by voxel in the tumors, providing maps of the ABrix (amplitude), kep 
and kel parameters. The median of a given parameter was extracted 
for each patient, in addition to a relative measure of tumor 
heterogeneity (difference between 66th and 33rd percentile, divided by 
the median). Cohort data for each center was compared using Mann-
Whitney tests. P-value<0.05 was considered statistically significant. 
Results: The cohort-based median values for center 1 versus center 2 
was 2.20 vs 3.41 (relative units), 1.59 vs 0.68 (min-1) and 0.076 vs 
0.080 (min-1) for ABrix, kep and kel, respectively. For the heterogeneity 
measure, values obtained were 0.40 vs 0.55, 0.54 vs 0.99 and 1.10 vs 
1.70, respectively. Non-significant differences were only found for 
median values of kel. 
Conclusions: Five out of six pharmacokinetic tumor parameters 
obtained from DCEMRI performed at the two different institutions 
were significantly different in this preliminary analysis, possibly 
pointing at differences in MR scanners and acquisition protocols. We 
aim at including patients from more institutions, at introducing the 
‘Tofts’ pharmacokinetic model and at using reference tissue for 
normalization. Furthermore, data are to be analyzed in a multivariate 
setting, accounting for variations in stage, tumor volume and other 
relevant clinical factors. 
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Purpose/Objective: Nowadays, quantitative 3D Ultrasound (US) Image 
Guided Radiotherapy (IGRT) systems are available which can assess 
absolute volumetric information on soft tissue. Acquiring daily US 
images is quick and imposes no extra radiation burden to the patient. 
For intramodality US systems only the reference CT (planning) image 
is available. Nevertheless, CT images for every treatment fraction 
would be useful, e.g. for dose recalculation, and assessing margins. To 
this end, deformable image registration (DIR) was applied to calculate 
the deformation field between reference and daily US images. This 
field was then applied to the reference CT.  
Materials and Methods: To validate the procedure a deformable 
phantom was developed, existing of a PMMA box filled with 
demineralized water, containing two balloons filled with either saline 
solution or sunflower oil with a variable volume. Four different 
configurations were imaged with CT as well as US. Deformation fields 
are computed between several pairs of US images and then applied to 
the corresponding CT of the first US of the pair (see figure). This 
reconstructed new, matching CT for the second US is then compared 
to the real corresponding CT of the second US using the sum of 
squared differences (SQD) metric. The deformation fields are 
calculated using an elastic registration algorithm (REGGUI; morphons). 
The SQD metric was limited to the area where US information was 
available.  
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Results: The DIR performs well visually and the sum of squares for the 
difference between the deformed CTs and the real CTs ranged 
between 4x109 and 5x109. For comparison, the difference between 
four volumes in which only noise generates differences between the 
images, gave a comparable SQD of around 3.7 x 109. For all the image 
pairs, the SQD of the deformed CTs is approximately half of that of 
the non-registered images (ranging from 0.45 to 0.59).  
Conclusions: A limitation of an US based deformation field is that the 
area of the CT on which one can perform the deformation field is 
limited to the area of which US data is available. However, this 
phantom experiment does show that the application of such an US 
based CT DIR in principle could work. Whether the US based CT DIR is 
also valid for patient cases, has to be studied further with patient 
examples.  
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Purpose/Objective: To assess the impact of respiratory-gated PET-CT 
(4D-PET-CT) on SUV quantification in lung tumors. 
Materials and Methods: 19 patients with lung tumors who had 18FDG-
PET-CT were studied with a 4D-PET-CT additional acquisition after a 
whole body scan. Patients were selected among the group that 
showed respiratory-induced tumor motion greater than 5 mm. 4D-PET-
CT was performed by means of a Philips Gemini BigBore TOF scanner 
capable of time-of-flight reconstruction, using the Varian RPM gating 
system. Administration and acquisition parameters were 3.0 MBq/kg 
18FDG, 2 min/bed, retrospective-mode for both PET and CT 
modalities. Patients were instructed to breath as regularly as possible. 
Data were reconstructed in 1 (no sorting), 4, 5, 6, 7, 8, 9 and 10 
breathing phases. SUVmax values within the lesion were studied as a 
function of the number of phases in phase(0%) (max expiration). 
Lesion volumes were also obtained by three different methods: a) 
fixed SUV=2.2 threshold, b) 40% of SUVmax isocontour and c) gradient-
based method. The volumes were also studied as a function of the 
number of phases in phase(0%). 
Results: The observed maximum range of motion was 5.5mm(L-R), 
16.5mm(A-P) and 22.2mm(S-I). SUVmax was on average 67.4% higher 
in the gated acquisition (10 phases) compared to the non-gated case 
(range 13.1%-328.3%). When comparing reconstructions in 4 and 10 
phases, the average increase in SUVmax reduced to 13.3% (range 2.3%-
31.2%). Corresponding figures for 6 to 10-phase comparison were 6.8% 
and range 0.0%-23.1%. In general, volumes estimated by the fixed-
threshold method increased with increasing phase number, volumes 
obtained with the percentage method decreased and volumes 
obtained with the gradient-based method did not show a significant 
trend. On average, volumes calculated in the 10-phase ph(0) image by 
method a) were 8.9% higher than volumes obtained by method b), 
while in the static acquisition (no gating) method a) gave volumes 20% 
smaller than method b), on average. 
Conclusions: 4D-PET-CT offers a clear advantage in 18F-FDG SUV 
estimation for tumors that move with respiration. The balance 
between acquisition/reconstruction time, signal-to-noise ratio and 
SUV estimation accuracy seems to be achievable splitting the 
respiratory cycle into 4 to 6 phases, depending on lesion location. The 
same observation holds for lesion volumes, however further research 
is needed to determine the optimal segmentation method. Gradient-
based methods are less sensitive to the number of phases for volume 
estimation, however further study is necessary to fine-tune and 
validate their results. 
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Purpose/Objective: Quantitative objective analyses are widely used 
in radiology. These are relevant in oncology as well, since the use of 
pelvic CBCT for adaptive RT requires a certain level of image quality. 
The purpose of this study is to objectively evaluate the clinical image 
quality of two systems; a state-of-the-art CBCT system and a new 
CBCT system with improved reconstruction and hardware.  
Materials and Methods: The patients included in this retrospective 
study had a planning CT and CBCT's from Clinac iX as well as 
Truebeam (Varian Medical Systems). Based on European Guidelines 
provided by CEC seven quality criteria in relation to the bladder on 
CBCT were defined along with an ordinal rating scale reflecting the 
fulfillment of a particular criterion. The corresponding author and a 
number of physicians rated in a randomized order the CT's and the 
pelvic CBCT's. The resulting data were evaluated by a statistical 
analysis called Visual Grading Characteristics (VGC) in the free 
software DBM MRMC 2.32 Build 3. The difference in image quality 
between the two modalities was evaluated by the area under the 
curve (AUC) and ANOVA. An AUC of 0.5 indicated equally image 
quality whereas higher values indicated superior image quality. If 0.5 
was not included in the 95% confidence interval the difference in 
image quality of the systems was significant. A VGC curve comprising 
the total image quality criteria was found for each observer. 
Furthermore, the impact of the individual criteria was demonstrated 
by a VGC curve and the respective AUC. The Image Criteria Score (ICS) 
was calculated for the total and individual criteria and ideally ICS 
would equal 1.0. As a reference the VGC analysis of the CT was 
performed.  
Results: An excerpt of the results of the corresponding author is 
included for five criteria (Figure 1). The VGC curves clearly illustrate 
better performance of Truebeam than Clinac iX for criterion I-IV, 
whereas the performance is more equivocal regarding criterion V. The 
AUC was 0.68 for the total quality criteria and the 95% confidence 
interval was [0.55, 0.80]. For criterion I the AUC was 0.72, criterion II 
yielded an AUC of 0.71, criterion III an AUC of 0.73, criterion IV an 
AUC of 0.70 and for criterion V AUC was 0.47. The total ICS for 
Truebeam and Clinac iX was 0.49 and 0.27, respectively. For the 
individual criteria the ICS was higher for Truebeam than Clinac iX. The 
percentage difference ranged between 11.1 and 33.3 percentage 
points. 
